Cargando…
Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty
PURPOSE: Gonadotropin-releasing hormone agonist (GnRHa) is used as a therapeutic agent for central precocious puberty (CPP); however, increased obesity may subsequently occur. This study compared body mass index (BMI) and insulin resistance during the first year of GnRHa treatment for CPP. METHODS:...
Autores principales: | Park, Jina, Kim, Jae Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Pediatric Endocrinology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401819/ https://www.ncbi.nlm.nih.gov/pubmed/28443256 http://dx.doi.org/10.6065/apem.2017.22.1.27 |
Ejemplares similares
-
Effects of Gonadotropin-Releasing Hormone Agonist Therapy on Body Mass Index and Height in Girls with Central Precocious Puberty
por: Lee, Seung Jae, et al.
Publicado: (2012) -
Effect of gonadotropin-releasing hormone agonist therapy on body mass index and growth in girls with idiopathic central precocious puberty
por: Anık, Ahmet, et al.
Publicado: (2015) -
The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty
por: Kim, Sung Woo, et al.
Publicado: (2017) -
Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty
por: Kim, Hye Ryun, et al.
Publicado: (2017) -
The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty
por: Yoon, Jong Wan, et al.
Publicado: (2017)